When people get the shots, the body’s immune system can accidentally confuse a normal protein from adenovirus - which is used ...

A rare but serious clotting disorder linked to certain COVID-19 vaccines and natural adenovirus infections has puzzled scientists for years. An international team of researchers from (Canada), ...

Flu activity remains elevated across Tennessee, with parts of East Tennessee reporting some of the highest levels of ...

The FDA declined to review Moderna's mRNA influenza vaccine due to inadequate clinical trial comparators for older adults.

Health and Human Services (HHS) Secretary Robert F. Kennedy Jr.’s first year in office has upended decades of public health ...

Q4 2025 earnings call highlights: revenue, cost cuts, cash outlook, FDA flu setback, and 2026 growth guidance—read key insights now.

Years later, we now have a much better idea of the side affects.

Moderna (NASDAQ: MRNA) reported fourth-quarter results Friday morning that beat Wall Street’s muted expectations, delivering revenue of $678 million against estimates of $663 million and a loss of $2.

Moderna (NASDAQ:MRNA) is escalating its standoff with US regulators at a delicate juncture in its post-pandemic reset. On Friday's analyst call, Chief Executive Officer Stephane Bancel described the ...

Five months after Republican Sen. Bill Cassidy invited Health and Robert F. Kennedy Jr. to testify in an oversight hearing, ...

Polling found that nearly 30% of older adults chose not to receive flu or COVID-19 vaccines due to a perceived lack of need.